You are hereNovember 13, 2017
What’s the Stem Cells Buzz this Week? - Boosting hMSC Osteogenesis, Accelerating Stem Cell Trials, Investigating Impaired Cardiac Repair, and Maintaining HCC CSCs!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
RUNX2 Programs hMSC Osteogenesis
Human mesenchymal stem cells (hMSCs) may possess tri-lineage differentiation potential, but stimulating high levels of osteogenesis has proven a tricky proposition. A new report from the lab of James E. Dixon (University of Nottingham, United Kingdom) now describes an efficient new osteogenic strategy: the application of non-virally derived recombinant RUNX2 protein via the glycosaminoglycan-binding enhanced transduction (GET) delivery system (GET-RUNX2). Excitingly, the high transduction efficiency of the GET system allowed GET-RUNX2 to trigger osteogenesis in hMSCs by enhancing target gene expression directly. For all the details on this approach to repair bone trauma and disorders without genetic modifications, see STEM CELLS Translational Medicine now!
Accelerating Stem Cells Clinical Trials via Nursing Competencies
A recent Perspective article from Rodica Stan describes the experience of the establishment of a California Institute for Regenerative Medicine-associated Alpha Stem Cell Clinic at the City of Hope (California, USA). Perrin et al. report the definition of the “hybrid nurse” role, a person with nursing competencies in both clinical care and research, as the highlight of the process and the key to success. Head over to STEM CELLS Translational Medicine now to understand how nursing competencies play a crucial role in the stem cell clinic.
Impaired Cardiac Repair in Diabetes: A Role for SDF-1:CXCR4
Diabetes causes impaired post-acute myocardial infarction (AMI) cardiac repair, and a new STEM CELLS Translational Medicine study from the lab of Feng Dong (Northeast Ohio Medical University, Ohio, USA) sought to figure out why! Mayorga et al. now report the dysregulation of the SDF-1:CXCR4 axis, which controls the mobilization and migration of stem cells from the BM to the site of tissue injury, in a disease-specific mouse model. However, this new STEM CELLS Translational Medicine study also demonstrates that overexpression of SDF-1 may represent a potentially exciting treatment option.
Translation Elongation Factor Helps to maintain Hepatocellular Carcinoma CSCs
Deciphering the mechanisms that regulate cancer stem cells (CSCs) may permit the development of potent anti-cancer therapies. In a previous study, researchers from the lab of Dan Xie (Sun Yat-Sen University Cancer Center, Guangzhou, China) demonstrated that overexpression of the eukaryotic initiation factor 5A2 (EIF5A2) promoted hepatocellular carcinoma (HCC) cell metastasis and angiogenesis. Now, their new STEM CELLS study suggests that EIF5A2 contributes to the maintenance of HCC CSCs via the c-Myc/miR-29b axis, raising the possibility of developing a new CSCs‐specific therapy.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!